Campbell Donald R, Senger Christiana N, Ryan Amy L, Magin Chelsea M
Department of Bioengineering, Denver, Anschutz Medical Campus, University of Colorado, Aurora, CO, United States.
Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Hastings Center for Pulmonary Research, University of Southern California, Los Angeles, CA, United States.
Front Med (Lausanne). 2021 Apr 8;8:647834. doi: 10.3389/fmed.2021.647834. eCollection 2021.
Biomaterials intentionally designed to support the expansion, differentiation, and three-dimensional (3D) culture of induced-pluripotent stem cells (iPSCs) may pave the way to cell-based therapies for chronic respiratory diseases. These conditions are endured by millions of people worldwide and represent a significant cause of morbidity and mortality. Currently, there are no effective treatments for the majority of advanced lung diseases and lung transplantation remains the only hope for many chronically ill patients. Key opinion leaders speculate that the novel coronavirus, COVID-19, may lead to long-term lung damage, further exacerbating the need for regenerative therapies. New strategies for regenerative cell-based therapies harness the differentiation capability of human iPSCs for studying pulmonary disease pathogenesis and treatment. Excitingly, biomaterials are a cell culture platform that can be precisely designed to direct stem cell differentiation. Here, we present a closer look at the state-of-the-art of iPSC differentiation for pulmonary engineering, offer evidence supporting the power of biomaterials to improve stem cell differentiation, and discuss our perspective on the potential for tissue-informed biomaterials to transform pulmonary regenerative medicine.
特意设计用于支持诱导多能干细胞（iPSC）扩增、分化及三维（3D）培养的生物材料，可能为慢性呼吸道疾病的细胞疗法铺平道路。全球数百万人饱受这些疾病折磨，它们是发病和死亡的重要原因。目前，大多数晚期肺部疾病尚无有效治疗方法，肺移植仍是许多慢性病患者的唯一希望。关键意见领袖推测，新型冠状病毒COVID-19可能导致长期肺部损伤，进一步加剧对再生疗法的需求。基于细胞的再生疗法新策略利用人类iPSC的分化能力来研究肺部疾病发病机制和治疗方法。令人兴奋的是，生物材料是一种可精确设计以引导干细胞分化的细胞培养平台。在此，我们深入探讨用于肺部工程的iPSC分化的最新进展，提供证据支持生物材料改善干细胞分化的能力，并讨论我们对组织信息生物材料转化肺部再生医学潜力的看法。
